Jafron DPMAS of New Technology Unveiled in Beijing

time :  2015-07-10

Jafron DPMAS of New Technology Unveiled in Beijing, Experts Praised as Therapeutic Strategy to Deal with the Shortage of Blood Plasma

On 10th July, Eighth National difficult and severe liver disease conferences opened in Beijing National Convention Center. Nearly 1,200 delegates from home and abroad, 20 participants pharmaceutical companies, Jafron carrying artificial liver technology patented dual plasma molecular adsorption system (DPMAS), DX-10 Blood purification machine and other new technologies, new products unveiled.

Convention regarded "Difficult and Severe Liver 10-Year History - Achievements, Challenges, Future" as the theme, started to explore new progress, new experiences and new technologies in the field of liver disease in China and worldwide. On the base of the previous success in seven conventions, increasing difficult liver disease, severe liver disease, liver disease cross-content technology and research advances in clinical and practical subjects.

Duan Zhongping, National difficult and severe liver disease research collaboration group leader, vice president of Capital Medical University Beijing You An Hospital, presidency of the conference and made an opening statement. He Jinqiu ,vice chairman of Liver Disease Branch of severe hepatitis with artificial liver of the Chinese Medical Association study group, director of Nanchang Ninth Hospital made a presentation entitled "Under the conditions of the plasma shortage of non-bioartificial liver treatment strategies," presented to the experts a variety of artificial liver plasma saving mode, and particularly presented on the principles of Jafron DPMAS treatment technology and clinical efficacy, emphasizes DPMAS technology is an important treatment modality in the current situation of plasma resource constraints, many experts resonated the view. Professor Ye Weijiang, Chinese Medical Association Hepatology severe liver and artificial liver with the National Study Group committee, also pointed out that the study showed that simply CVVH does not reduce mortality in patients with sepsis, but using a combination of blood adsorption techniques to increase the rate of successful treatment for patients was statistically significant. Professor Ye Jian also mentioned the use of Jafron Hemoperfusion Cartridge is better than Japan Adsorber.

During the conference, many participants also showed great interest in the price and other details of the DX-10 Blood purification machine and made some consultation.

The conference, jointly organized by the Department of Medicine Jieping Medical Foundation liver disease, severe liver disease and difficult national research cooperative group, Beijing Chinese Medicine Association of Science and Technology, Capital Medical University, Institute of Medical Science and Technology Park liver transformation. During the conference, it also announced new list of 54 National Commissions of "national difficult and severe liver disease research coordination group".

the conference scene.jpg

the conference scene

Professor He Jinqiu introduced DPMAS technology.jpg

Professor He Jinqiu introduced DPMAS technology

Professor Duan Zhongping visit Jafron's booth.jpg

Professor Duan Zhongping visit Jafron's booth

Introduction of DX-10 blood purification machine.jpg

Introduction of  DX-10 blood purification machine